|
HOSHINO Junichi
Department School of Medicine(Tokyo Women's Medical University Hospital), School of Medicine Position Professor and Division head |
|
| Article types | Original article |
| Language | English |
| Peer review | Non peer reviewed |
| Title | Glomerular Microangiopathy with Cellular Crescent-like Formation and Endotheliopathy Due to Ramucirumab Treatment for Metastatic Sigmoid Colon Cancer. |
| Journal | Formal name：Internal medicine (Tokyo, Japan) Abbreviation：Intern Med ISSN code：13497235/09182918 |
| Volume, Issue, Page | 61(23),pp.3547-3552 |
| Author and coauthor | Yoshimura Yusuke, Sawa Naoki, Matsuoka Shusaku, Ikuma Daisuke, Oba Yuki, Sekine Akinari, Hasegawa Eiko, Mizuno Hiroki, Yamanouchi Masayuki, Suwabe Tatsuya, Hoshino Junichi, Kono Kei, Kinowaki Keiichi, Ohashi Kenichi, Toda Shigeo, Matoba Shuichiro, Wakui Hideki, Ubara Yoshifumi |
| Publication date | 2022/12 |
| Summary | We encountered a 77-year-old Japanese man who presented with nephrotic-range proteinuria 20 days after receiving ramucirumab treatment for metastatic sigmoid colon cancer. A kidney biopsy showed two characteristic histological findings. The first finding was podocyte injury with cellular crescent-like formation, although focal segmental glomerulosclerosis (FSGS) (collapsing variant) according to the Columbia classification may have been a more appropriate name for this injury, as hypertrophy and hyperplasia of epithelial cells, presumably resulting from podocyte injury, were seen between Bowman's capsule and the glomerular basement membrane (GBM); these changes appeared to be due to the collapse of the GBM rather than to GBM destruction with fibrinoid necrosis. The second finding was endotheliopathy characterized by prominent mesangial interposition via enlargement of the mesangial matrix with mesangiolysis. Proteinuria and renal dysfunction subsided after discontinuation of ramucirumab. Bevacizumab has been reported to induce glomerular microangiopathy with endothelial damage and swelling six months after treatment, but in this case, ramucirumab may have induced focal segmental glomerulosclerosis (FSGS) collapsing variant and glomerular microangiopathy with endotheliopathy via mesangial damage within 1 month. We believe that the damage to the glomerular podocyte and endothelial cells via mesangial damage secondary to ramucirumab in our patient was a different type of glomerular microangiopathy than the endothelial cell damage with enlargement of the subendothelial space caused by bevacizumab. |
| DOI | 10.2169/internalmedicine.9185-21 |
| PMID | 35569979 |